Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero

AIDS

Volumn 13, Issue 8, 1999, Pages 919-925

  Olivero, Ofelia A ^a   Shearer, Gene M ^a   Chougnet, Claire A ^a   Kovacs, Andrea A S ^b   Landay, Alan L ^c   Baker, Robin ^d   Stek, Alice M ^b   Khoury, Margaret M ^b   Proia, Laurie A ^c   Kessler, Harold A ^c   Sha, Beverly E ^c   Tarone, Robert E ^a   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Fairfax Hospital   (United States)

Author keywords

3'azido 3' deoxythymidine; AIDS; HIV 1; Peripheral blood mononuclear cells; Radioimmunoassay

Indexed keywords

CELL DNA; ZIDOVUDINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DELIVERY; DNA DAMAGE; DNA DETERMINATION; FEMALE; FETUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTAGENICITY; PHOSPHORYLATION; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; UMBILICAL CORD BLOOD;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DNA; FEMALE; FETAL BLOOD; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; LEUKOCYTES, MONONUCLEAR; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; ZIDOVUDINE;

EID: 0033007828     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199905280-00007     Document Type: Article

References (28)

1. Ayers KM, Clive D, Tucker WE, Hajian G, de Miranda P. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundament Appl Toxicol 1996, 32:148-158.
2. NTP. Toxicology and Carcinogenesis Studies of AZT. Research Triangle Park, NC: National Toxicology Program; 1996.
3. Olivero OA, Beland FA, Fullerton NF, Poirier MC. Vaginal epithelial DNA damage and expression of preneoplastic markers in mice during chronic dosing with tumorigenic levels of 3′-azido-2′,3′-dideoxythymidine (AZT). Cancer Res 1994, 54:6235-6242.
4. Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3′-azido-2′,3′-dideoxythymidine (AZT): tumorigenicity in mice and genotoxitity in mice and monkeys. J Natl Cancer Inst 1997, 89:1602-1608.
5. Diwan BA, Olivero OA, Haines DC, et al. Transplacental carcinogenicity of 3′-azido-3′-deoxythymidine (AZT) in mice[Abstract]. Proc Am Assoc Cancer Res 1998, 39:21.
6. Zhang Z, Diwan BA, Anderson LM, et al. Skin tumorigenesis and K-ras and H-ras mutations in tumors from adult mice exposed in utero to 3′-azido-2′,3′-dideoxythymidine (AZT). Mol Carcinog 1998, 23:45-51.
7. Miller JA, Miller EC. Perspectives on the metabolism of chemical carcinogens. Amsterdam: Elsevier/North-Holland Biomedical Press; 1979.
8. Beland FA, Poirier MC. DNA adducts and carcinogenesis. In Pathobiology of Neoplasia. Edited by Sirica AE. New York: Plenum Press; 1989:57-80.
9. Poirier MC. Concepts and mechanisms in carcinogen-DNA interactions. In Control Mechanisms of Carcinogenesis. Edited by Hengstler, JG, Oesch F. Meissen, FRG: Druckeri Thieme; 1995:193-220.
10. Dertinger SD, Iorous DK, Tometsko KR. Induction of micronuclei by low doses of azidothymidine (AZT). Mutat Res 1996, 368;301-307.
11. Gonzalez CM, Larripa I. Genotoxicity of azidothymidine (AZT) in in vitro systems. Mutat Res 1994, 321:113-118.
12. Sussman HE, Olivero OA, Pietras SM, et al. Genotoxicity of 3′-azido-3′-deoxythymidine (AZT) in the human lymphoblastoid cell line TK6. Environmental and Molec. Mutag 1999 33:63, [abstract 213].
13. Grdina DJ, Dale P, Weichselbaum R. Protection against AZT-induced mutagenesis at the HGPRT locus in a human cell line by WR-151326. Int J Radiat Oncol Biol Phys 1992, 22:813-815.
14. Sommadossi JP, Carlisle R, Zhou Z. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol Pharmacol 1989, 36:9-14.
15. Olivero OA, Beland FA, Poirier MC. Immunofluorescent localization and quantitation of 3′-azido-2′,3′-dideoxythymidine (AZT) incorporated into chromosomal DNA of human, hamster and mouse cell lines. Int J Oncol 1994, 4:49-54.
16. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
17. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996, 335:1621-1629.
18. Flamm WG, Birnstiel ML, Walker PMB. Preparation and fractionation and isolation of single strands of DNA by ultracentrifugation in fixed-angle rotors. In Subcellular Components: Preparation and Fractionation. Edited by Birnie GD, Fox SM. London: Butterworths; 1967: 126-154.
19. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden Day; 1975:212-238;297-303.
20. Kraemer KH, Levy DD, Parris CN, et al. Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer. J Invest Dermatol 1994, 103:965-1015.
21. Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine. An update. Clin Pharmacokinet 1996, 30:251-262.
22. Stretcher BN. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 1995, 29:46-65.
23. Veal GJ, Back DJ. Metabolism of zidovudine. Gen Pharmacol 1995, 26:1469-1475.
24. Peter K, Gambertoglio JG. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection. Pharm Res 1998, 15:819-825.
25. Levine AM, Bernstein L, Sullivan-Halley J, et al. Role of zidovudine antiretroviral therapy in the pathogenesis of acquired immunodeficiency syndrome-related lymphoma . Blood 1995, 86:4612-4616.
26. Pluda JM, Venzin DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 1993, 11:1099-1107.
27. Joffe MM, Hoover, DR, Jacobson LP, Kingsley L, Chmiel JS, Visscher BR. Effect of treatment with zidovudine on subsequent incidence of Kaposi's sarcoma. Clin Infect Dis 1997, 25:1125-1133.
28. Culnane MS, Fowler MG, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. J Am Med Assoc 1999, 281:151-157.